sulindac (clinoril) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Sulindac is a nonsteroidal anti-inflammatory agent (NSAIA) of the arylalkanoic acid class that is marketed in the U.S. by Merck as Clinoril. Like other NSAIAs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted in vivo to an active sulfide compound by liver enzymes. The sulfide metabolite then undergoes enterohepatic circulation; it is excreted in the bile and then reabsorbed from the intestine. This is thought to help maintain constant blood levels with reduced gastrointestinal side effects. Some studies have shown sulindac to be relatively less irritating to the stomach than other NSAIA's except for drugs of the cyclooxygenase-2 (COX-2) inhibitor class. The exact mechanism of its NSAIA properties is unknown, but it is thought to act on enzymes COX-1 and COX-2, inhibiting prostaglandin synthesis.   NCATS

Chemistry

  • SMILES: C[S+]([O-])C1=CC=C(\C=C2\C(C)=C(CC(O)=O)C3=CC(F)=CC=C23)C=C1
  • InChIKey: MLKXDPUZXIRXEP-MFOYZWKCSA-N
  • Mol. Mass: 356.411
  • ALogP: 4.37
  • ChEMBL Molecules:
    sulindac  
    exisulind  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1063 - $0.2384
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1h-indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene)-, (z)- | (5-fluoro-2-methyl-1-(3,4,5-trimethoxybenzylidene)-3-(n-benzyl)-indene)-acetamide | aptosyn | cis-5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1h-indene-3-acetic acid | cis-5-fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid | clinoril | cp248 | cp 248 | exisulind | fgn-1 | mk231 | mk 231 | mk-231 | osip486823 | osip 486823 | osip-486823 | sulindac | sulindaco | sulindac sulfone | sulindac sulfone, (z)-isomer | sulindacum | varnish | (z)-5-fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1h-indene-3-acetic acid

Organizations (52)

Research & Development (42)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (27)

Approved Indications (5)


 

Adenomatous Polyposis Coli

Arthritis, Rheumatoid (approved 1988)

Osteoarthritis (approved 1988)

Spondylitis

Spondylitis, Ankylosing (approved 1988)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Adenomatous Polyposis Coli (Phase 3)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 3)

Dental Caries (Phase 1)

Dermatology (Phase 2)

Fragile X Syndrome (Phase 2)

Hypertension (Phase 2)

Inflammation (Phase 2)

Intestinal Neoplasms (Phase 2/Phase 3)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Pain (Phase 2)

Pancreatic Intraductal Neoplasms (Phase 2)

Precancerous Conditions (Phase 3)

Prostatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Tobacco Use Disorder (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 40
  • # of Trial Organizations: 42

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue